在白血病中SIRT1的作用
Zhongqi Wu1,2, Tianxin Lyu3, Leizhen Wu4
1Department of Psychiatry, Henan Key Lab of Biological Psychiatry, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan of Xinxiang Medical University, Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Xinxiang, 453002, China.
Current treatment options in oncology
|October 2, 2024
概括
沉默信息调节器1 (SIRT1) 在白血病中起着双重作用,影响细胞生长和存活. 了解SIRT1的理解
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 白血病是一种复杂的血液性恶性瘤,具有具有挑战性的治疗结果.
- 尽管取得了进展,但由于疾病异质性,一些白血病患者仍然面临着不良预后.
- 沉默信息调节器1 (SIRT1) 已成为白血病细胞生物学中的关键因素.
研究的目的:
- 审查SIRT1在白血病中的多方面的作用.
- 在白血病的背景下阐明SIRT1的调节机制.
- 为开发针对SIRT1.1的新型白血病治疗提供理论基础.
主要方法:
- 关于SIRT1和白血病的最新研究的文献综述.
- 对SIRT1参与白血病细胞增殖,细胞亡,新陈代谢和衰老的分析.
- 对SIRT1的双重作用 (亲和抗白血病效应) 的当前知识的综合.
主要成果:
- SIRT1表现出"双刃剑"效应,影响白血病细胞生长的促进和抑制.
- SIRT1与关键的细胞过程有关,包括白血病中的增殖,亡,新陈代谢和衰老.
- 通过SIRT1调节白血病的确切机制仍然不完全理解.
结论:
- SIRT1是白血病的重要调节剂,影响多个细胞通路.
- 对SIRT1复杂机制的进一步研究对于改善白血病治疗策略至关重要.
- 向SIRT1可能为未来的白血病治疗干预提供了一个有希望的途径.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


